---
title: "Rani Therapeutics to present at Canaccord Genuity Annual Growth Conference"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295403455.md"
description: "Rani Therapeutics will participate in the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026, in Boston. CEO Talat Imran and CFO Nicholas Maestas are scheduled to present at 2:30 p.m. ET."
datetime: "2026-08-10T12:01:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295403455.md)
  - [en](https://longbridge.com/en/news/295403455.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295403455.md)
---

# Rani Therapeutics to present at Canaccord Genuity Annual Growth Conference

-   Rani Therapeutics will participate in the Canaccord Genuity 46th Annual Growth Conference on Aug. 12, 2026 in Boston. \* CEO Talat Imran will present alongside CFO Nicholas Maestas at 2:30 p.m. ET. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rani Therapeutics Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608100800PRIMZONEFULLFEED9806284) on August 10, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [RANI.US](https://longbridge.com/en/quote/RANI.US.md)

## Related News & Research

- [Rani Therapeutics CEO Imran Talat acquires 35,000 shares worth $25,193](https://longbridge.com/en/news/293391818.md)
- [Rani Therapeutics director, 10% owner Mir A. Imran buys 36,000 shares worth $24,840](https://longbridge.com/en/news/293661163.md)
- [Block CFO and COO Amrita Ahuja disposes of $770,219 of common shares](https://longbridge.com/en/news/295278385.md)
- [Amrize Ltd’s 2025 Risk Profile: Stable Disclosures, Persistent Vulnerabilities for Investors](https://longbridge.com/en/news/295624082.md)
- [Simris Q2 FY26 operating loss narrows 19% to SEK 5.44 million; revenue drops 71% to SEK 196,000](https://longbridge.com/en/news/295619223.md)